Senate Releases FDA Discussion Draft With Reforms for Diagnostic Testing

May 18, 2022 by Alexa Hornbeck
Senate Releases FDA Discussion Draft With Reforms for Diagnostic Testing
An FDA microbiologist prepares to conduct tests for high risk pathogens in a biosafety laboratory. (FDA Flickr)

WASHINGTON — Members from the Senate Health, Education, Labor and Pensions Committee released a draft of the legislative package to reauthorize user fee agreements for the U.S. Food and Drug Administration on Tuesday, which are set to end on Oct. 1, 2022. 

“This bipartisan draft strengthens FDA’s foundation to ensure our review and approval process is ready for the next generation of innovative products. It also includes key measurements to ensure the agency meets its commitments and modernizes our diagnostic testing framework to bring certainty to test developers and give Americans confidence in their health care decisions,” said Sen. Richard Burr, R-N.C., who serves as ranking member of the Senate HELP Committee, in a press release on Tuesday.

The discussion draft of the FDA Safety and Landmark Advancements Act, released by Burr and Sen. Patty Murray, D-Wash., who serves as committee chair of the Senate HELP Committee, would reauthorize the FDA’s prescription drug, generic drug, biosimilar and medical device user fee agreements.

The 409-page draft document was developed after the committee hearings with FDA officials and stakeholders last month. According to Burr, the mark up for the final version of the legislation will be released in the coming weeks.

The Subcommittee on Health of the Committee on Energy and Commerce released a draft version of the bill on May 4, and met to mark it up on May 11. 

The Senate draft of the FDA reauthorization legislation package released on Tuesday includes new oversight of cosmetics and dietary supplements, reauthorizes important programs for medical product development and aims to modernize diagnostic test regulation.

“The latest discussion draft from the reauthorization from the committee includes a discussion of the VALID act,” said Liz Richardson, project director of Health Care Products at Pew Charitable Trusts, during a phone call with The Well News.

The VALID Act, also known as the Verifying Accurate, Leading-edge IVCT Development Act, would establish a regulatory category called in vitro clinical tests, including current laboratory developed test services.

Richardson said the VALID Act would increase oversight of the FDA for in vitro diagnostics tests, which are tests which use human samples like blood or tissue to help clinicians diagnose and treat health conditions ranging from cancers, to suspected drug abuse, to lead poisoning.

“Many tests are just not reviewed by the FDA before they are used in clinical care, based on one regulatory decision made 40 years ago,” said Richardson.

“[The current] policy is no longer a good fit for the market. In order to adequately protect public health and drive decision making, we need to update the regulatory framework,” continued Richardson.

Richardson said concerns about how IVD tests are regulated has been on the FDA’s radar since the 1990s, but talks of the VALID Act have only been happening on the Hill for about six years. 

Richardson said that around 2014 the discussion for how the framework for diagnostics and laboratory developed tests would be reformed shifted to the legislator. 

The FDA released a discussion draft in 2016 called the Diagnostic Accuracy and Innovation Act following substantial input from the diagnostics and laboratory industry. This led to the first draft of the VALID Act in December 2018, which was a revision of the DAIA bill.

Richardson said most of the current FDA regulatory framework focuses on commercially manufactured tests, where clear authority is given to FDA to review.

“But for lab tests, for any tests developed or used in the same lab, as long as it never leaves the foreign walls of that lab, the FDA is not reviewing it, because of that policy enforcement discretion,” said Richardson.

Richardson said that part of the challenge with laboratory developed tests is that they are poorly tracked and highly fragmented. 

“Nobody knows how many are out there,” said Richardson.

“What we do know is there are a lot of LDTs in-use in certain fields—oncology, infectious disease, prenatal testing, and toxicology,” said Richardson.

Richardson said the lack of consistency in testing, especially in high-risk settings can be harmful to patients.

“If you sent a tumor sample to three different labs you would potentially get three different results, that’s why it’s a problem for patients,” said Richardson.

Richardson said that she and her research team have plans to submit a comment letter to the discussion draft released on Tuesday by the Senate HELP Committee. 

“The dynamics are complicated. I don’t know what will happen over the next month. Over the next couple weeks, lots of stakeholders will weigh in on VALID and try to get their changes into the bill,” said Richardson.

Not all members from the research community support the VALID Act, as some say it will hinder innovation. 

This is the position of The American Association for Clinical Chemistry, a global scientific and medical professional organization dedicated to clinical laboratory science and its application to health care, which has advocated against FDA regulations of LDTs since their first position statement on the issue in 2016. 

“The VALID Act would formalize FDA oversight of LDTs in addition to CMS oversight. As a result, many labs would be forced to stop developing LDTs, as they would not have the resources to meet these new, duplicative regulatory requirements. This in turn would hinder our ability to respond to emerging threats to health, such as new drugs of abuse,” Dr. Stephen R. Master, AACC president, chief, Division of Laboratory Medicine at Children’s Hospital of Philadelphia, associate professor, Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine, in an email to The Well News.

Master said that public health advocates and organizations have been debating LDT regulation ever since FDA first proposed bringing LDTs under its oversight in 2010.

The draft bill from the Senate HELP Committee would create a new user fee program that can be applied to laboratories performing LDTS, but Master said that there is an alternative approach — to modernize Clinical Laboratory Improvement Amendments, or CLIA.

Clinical laboratories are currently regulated by the Centers for Medicare and Medicaid Services under the CLIA.

The AACC position calls for modernizing CLIA and harnessing CMS’s already existing authority to ensure that laboratory developed tests are effective and safe, without introducing dual FDA-CMS oversight.

“We are confident that modernizing CLIA will effectively address concerns about LDTs … by hindering labs’ ability to perform LDTs, the VALID Act would ultimately stifle the field’s ability to progress,” said Master.

Alexa can be reached at [email protected]

A+
a-
  • diagnostic testing
  • Food and Drug Administration
  • Senate
  • In The News

    Health

    Voting

    Health

    Biden Announcing New Rule to Protect Consumers Who Purchase Short-Term Health Insurance Plans

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A... Read More

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A new rule finalized by the Democratic president's administration will limit these plans to just three months. And the plans can only be renewed for a maximum... Read More

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    News From The Well
    scroll top